DiaSorin (OTCMKTS:DSRLF) Sees Strong Trading Volume – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) saw strong trading volume on Thursday . 300 shares were traded during mid-day trading, an increase of 148% from the previous session’s volume of 121 shares.The stock last traded at $85.78 and had previously closed at $73.85.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Zacks Research raised shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, DiaSorin currently has an average rating of “Hold”.

DiaSorin Stock Up 7.2%

The company’s 50 day moving average is $68.84 and its 200 day moving average is $74.48.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.